Royalty Pharma competitor stirs the pot with plans for $750M IPO
Ostensibly aiming to piggyback off the success of Royalty Pharma and CEO Pablo Legorreta’s IPO in June 2020, another royalty-gobbling company is nearly set to do the Nasdaq shuffle.
Healthcare Royalty, a Stamford, CT-based company founded by life sciences investing vet Clarke Futch, has set the terms for a $750 million IPO expected to price next week, according to Renaissance Capital. The likely figure is still dwarfed by Legorreta’s $2.2 billion raise a little over a year ago, but should Healthcare Royalty match its terms, it would be larger than any biotech IPO so far in 2021, per the Endpoints News tally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.